KROS Jun 2024 75.000 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

24.00

0.00

(0.00%)

As of 11:03AM EDT. Market open.

Loading interactive chart...

GuruFocus.com
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
Simply Wall St.
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...